Arthritis 695. de Boysson H, Arquizan C, Touz E, Zuber M, Boulouis G, Naggara O, Guillevin L, Aouba A, Pagnoux C. Treatment and long-term outcomes of primary central nervous system vasculitis. Stroke. 2018;49:1946 1952. 696. Schuster S, Ozga AK, Stellmann JP, Deb-Chatterji M, H u ler V, Matschke J, Gerloff C, Thomalla G, Magnus T. Relapse rates and long-term outcome in primary angiitis of the central nervous system. J Neurol. 2019;266:1481 697. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621 698. Liou TH, Huang SW, Lin JW, Chang YS, Wu CW, Lin HW. Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci Rep. 2014;4:5110. doi: 10.1038/srep05110 699. Stojan G, Petri M. Atherosclerosis in systemic lupus erythemato- sus. J Cardiovasc Pharmacol. 2013;62:255 262. doi: 10.1097/ 700. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 701. Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm hydroxy- chloroquine therapy and low-dose aspirin may have an additive effective- ness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017;44:1032 1038. doi: 702. Law ST, Ma KM, Li KK. Clinical characteristics of concurrent and se- quentially presented lupus-related protein-losing enteropathy: what are their differences? Rheumatol Int. 2013;33:85 92. doi: 10.1007/ 703. Shapiro M, Levy Y. The association between hydroxychloroquine treat- ment and cardiovascular morbidity among rheumatoid arthritis patients. 704. 